<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31795746</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1-2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>130</EndPage><MedlinePgn>123-130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2019.1682614</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal, rare, and hard to diagnose neurological disease with unknown etiology. <i>Objective</i>: To understand the incidence, prevalence, and survival characteristics of ALS cases in the Atlanta metropolitan area. <i>Methods</i>: Neurologists in Clayton, Cobb, DeKalb, Fulton, and Gwinnett counties provided case reports for ALS patients under their care from 1 January 2009 to 31 December 2011. Incidence and prevalence rates were calculated for 2009, 2010, and 2011 by sex, race, and ethnicity. Using data from the National Death Index, survival time was calculated for age, sex, race, ethnicity, and El Escorial criteria. <i>Results</i>: There were 281 unique ALS cases reported, which is approximately 104% of the expected cases. The majority of the 281 cases were white, non-Hispanic, male, and in the 50-59 age category. The overall average incidence rate for 2009 to 2011 was 1.54 per 100,000 person-years, with higher annual incidence rates for whites, males, and non-Hispanics. The prevalence rates for 2009, 2010, and 2011 were 5.05, 5.44, and 5.56 per 100,000, respectively. Median survival time was highest for the 18-39 age group, Asians, non-Hispanics, and males. Additionally, the log-rank tests for homogeneity across strata indicate a statistical significance between strata for the age category for survival time. <i>Conclusion</i>: The findings for Atlanta are similar to other population-based studies in the United States. Although the Atlanta metropolitan area was selected to over-represent the minority population, the strongest predictor of survival time was age at diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Punjani</LastName><ForeName>Reshma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, GA, USA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, GA, USA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="Y">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008913" MajorTopicYN="N">Minority Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="Y">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="Y">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Atlanta</Keyword><Keyword MajorTopicYN="N">National ALS Registry</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">minority populations</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword><Keyword MajorTopicYN="N">survival characteristics</Keyword></KeywordList><CoiStatement>Declaration of interest. The authors declare no conflicts of interest. The conclusions of this article are those of the authors and do not necessarily represent the views of ATSDR, the Centers for Disease Control and Prevention (CDC), or the U.S. Department of Health and Human Services (HHS).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31795746</ArticleId><ArticleId IdType="mid">NIHMS1696590</ArticleId><ArticleId IdType="pmc">PMC8130365</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1682614</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon PH. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. A&amp;D. 2013;04:295&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794725</ArticleId><ArticleId IdType="pubmed">24124634</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:623&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Logroscino G, Chi&#xf2; A, Hardiman O, Millul A, Mitchell D, et al. Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. Amyotrophic Lateral Scler. 2010;11:289&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513269</ArticleId><ArticleId IdType="pubmed">20433412</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallis BA, Hardiman O. Aggregation of neurodegenerative disease in ALS kindreds. Amyotrophic Lateral Scler. 2009;10:95&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608094</ArticleId></ArticleIdList></Reference><Reference><Citation>Das K, Nag C, Ghosh M. Familial, environmental, and occupational risk factors in development of amyotrophic lateral sclerosis. North Am J Med Sci. 2012;4:350&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421913</ArticleId><ArticleId IdType="pubmed">22912943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the &#x2018;common&#x2019; neurologic disorders?. Neurology. 2007;68:326&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17261678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi Y, Atsuta N, Sobue G, Morita M, Nakano I. Prevalence and incidence of amyotrophic lateral sclerosis in Japan. J Epidemiol. 2014;24:494&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213224</ArticleId><ArticleId IdType="pubmed">25373461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis &#x2014; United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner L, Archer NP, Williamson DM, Henry JP, Schiffer R, Jackson CE, et al. Prevalence of amyotrophic lateral sclerosis in Texas, 1998&#x2013;2003. Texas Med. 2012;108:e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22714948</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, van den Eeden SK, Tanner CM, Bernstein AL. Incidence of amyotrophic lateral sclerosis in a multiethnic health care organization. Neuroepidemiology. 2010;34:276.</Citation></Reference><Reference><Citation>Pupillo E, Messina P, Logroscino G, Beghi E. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol. 2014;75:287&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan H, Fagliano J, Rechtman L, Lefkowitz D, Kaye W. Effects of demographic factors on survival time after a diagnosis of amyotrophic lateral sclerosis. Neuroepidemiology. 2015;44:114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4533862</ArticleId><ArticleId IdType="pubmed">25792423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, Rath J, Fuzi J, Reichardt B, Fulop G, Koppi S, et al. Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology. 2015;44:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25571962</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulukonis ST, Roberts EM, Valle JP, Collins NN, English PB, Kaye WE. Survival and cause of death among a cohort of confirmed amyotrophic lateral sclerosis cases. PLoS One. 2015;10:e0131965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501568</ArticleId><ArticleId IdType="pubmed">26172548</ArticleId></ArticleIdList></Reference><Reference><Citation>Antao VC, Horton DK. The National Amyotrophic Lateral Sclerosis (ALS) Registry. J Environ Health. 2012;75:28&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549968</ArticleId><ArticleId IdType="pubmed">22866401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States. Amyotrophic Lateral Scler Frontotemporal Degener. 2014;15:433&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587982</ArticleId><ArticleId IdType="pubmed">24597459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner L, Rechtman L, Jordan H, Ritsick M, Sanchez M, Sorenson E, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotrophic Lateral Scler Frontotemporal Degener. 2015;23:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4732418</ArticleId><ArticleId IdType="pubmed">26399278</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disorder. 2000;1:293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Microsoft Excel [computer program]. Redmond, Washington: Microsoft; 2016</Citation></Reference><Reference><Citation>SAS Institute Inc. [computer program]. Base SAS&#xae; 9.3 Procedures Guide. Cary, NC: SAS Institute Inc; 2011.</Citation></Reference><Reference><Citation>US Census Bureau. Race and Hispanic or Latino Origin 2010, 2010 Census Summary. Washington, DC: US Department of Commerce, US Census Bureau; 2010. Available at: https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=CF</Citation></Reference><Reference><Citation>Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, et al. Prevalence of Amyotrophic Lateral Sclerosis &#x2013; United States, 2010-2011. MMWR Surveill Summ. 2014;63:1&#x2013;14.</Citation></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragonese P, Cellura E, Aridon P, D&#x2019;amelio M, Spataro R, Taiello AC, et al. Incidence of amyotrophic lateral sclerosis in Sicily: a population-based study. Amyotrophic Lateral Scler. 2012;13:284&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22409362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68:1002&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17389304</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M, Marin B, Nichols E, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol. 2018;17:1083&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Logroscino G, Boum&#xe9;diene F, Labrunie A, Couratier P, Babron M-C, et al. Clinical and demographic factors and outcomes of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur J Epidemiol. 2016;31:229.</Citation><ArticleIdList><ArticleId IdType="pubmed">26458931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population. Neurology. 2009;72:1640&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433736</ArticleId></ArticleIdList></Reference><Reference><Citation>Freer C, Hylton T, Jordan HM, Kaye WE, Singh S, Huang Y, et al. Results of Florida&#x2019;s Amyotrophic Lateral Sclerosis Surveillance Project, 2009&#x2013;2011. BMJ Open. 2015;5:e007359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410133</ArticleId><ArticleId IdType="pubmed">25900464</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle J, Roberts E, Collins N, Paulukonis S, English P, Kaye W. Epidemiology and surveillance of amyotrophic lateral sclerosis in two large metropolitan areas in California. Amyotrophic Lateral Scler Frontotemporal Degener. 2015;16:209&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544858</ArticleId><ArticleId IdType="pubmed">25822003</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population-based study, 1996&#x2013;2000. J Neurol Neurosurg Psychiatry. 2003;74:1258&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738639</ArticleId><ArticleId IdType="pubmed">12933930</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S, Trevor-Jones E, Khan S, Shaw K, Marchment D, Kulka A, et al. The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotrophic Later Scler Fr. 2017;18:569&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">28719997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>